What We Do

More expertise. Deeper insights.

Biopharma is a world of big rewards, and even bigger risks. Since 1992, biopharma companies have turned to Health Advances for business strategies that help maximize the former while minimizing the latter.

Because healthcare is our sole focus, Health Advances quickly integrates knowledge from a clinical, technical, and business perspective to create strategies that guide your most critical business decisions.

How We Help Your Business

Winning strategies. Real results.

Our Biopharma team of scientists, physicians, and industry experts has a deep working knowledge of the healthcare industry and its stakeholders. We tackle the challenges of drug development, market access, and commercialization. Our teams partner with clients to:

  • Translate emerging science into compelling products backed by actionable development and commercialization strategies.
  • Develop go-to-market roadmaps that anticipate the evolving healthcare market
  • Identify opportunities and implement strategies that maximize the value of franchises and companies
Examples

Here are some of the ways our Biopharma team is helping clients drive business value:

Vivek Mittal: “When an emerging biotechnology company with a promising tyrosine kinase inhibitor (TKI) suitable for multiple patient populations needed a strategy to maximize clinical development dollars, Health Advances was the firm of choice.

Andrew Funderburk: “Health Advances has a depth and breadth of scientific and business experience to understand both the key details and the big picture. We develop effective strategies and see them through. On a recent project, Health Advances assisted our client at every step in building a formidable CNS franchise, from defining a vision to completing a major acquisition.”

Sheela Hegde: “Over the years, we have built an unparalleled wealth of insights and expertise in the diabetes space. When our client needed a global forecast for a Phase 3 diabetes asset in a very aggressive timeline, they came to us because they knew we could deliver a level of market analysis and insight that others could not.”

Gary Gustavsen: “We recently completed a large project for a major biopharma that further validated the need for a globally-orchestrated, but locally-tailored companion diagnostic strategy. The barriers to CDx adoption across markets are unique; every country needs its own set of tactics.”

Wyatt Gotbetter: “For a leading manufacturer of generics and biosimilars, Health Advances helped develop a best-in-class design and strategy for launching an auto injector that will ensure our client exceeds all patient and clinician expectations, offering a top patient experience at better value.”

Featured Areas

We have well-established methodologies for:

Over 20+ years, we have built expertise across every therapeutic area and drug category. We have particular expertise in:

Our cross-sector expertise give us unique insights into:

View our biopharma case examples.

View our biopharma case studies.

Practice Leaders

Contact the Biopharma Team

Recent News, Events & Publications

Leveraging FDA’S Accelerated Pathways for Market Advantage

Andrew Funderburk, Partner, Sheela Hegde, Partner

Over the past 15 years, the FDA and Congress developed several accelerated pathways to provide incentives for manufacturers to develop innovative new drugs to treat conditions with substantial unmet need. The objective of this white paper is to describe recent trends in the use of the FDA’s accelerated pathways and to examine the market advantage associated with these pathways, particularly in oncology.

04.27.16

Health Advances Sponsors BSHP’s Evening of Hope

Boston, MA

Health Advances is proud to sponsor the Biomedical Science Careers Program’s (BSCP) Evening of Hope gala event as a “Hope Leader” on April 27, 2016. The event will honor two life science leaders and long-time friends of the firm, John Maraganore, PhD, CEO of Alnylam Pharmaceuticals, and Peter Slavin MD, President of Mass General Hospital.

BSCP was established in 1991 to increase the number of underrepresented minorities in the biomedical sciences and health professions. BSCP identifies academically outstanding minority students and trainees dreaming of a career in medicine, health care, science and biotechnology; and provides them with the information and support needed to achieve their goals through conferences, workshops, symposia, newsletters, scholarships and the BSCP Linkage Program.

The principal source of funds to support the critical mission of BSCP comes from sponsorships of Evening of Hope. As a result of the event, over 10,000 students and over 1,100 postdoctoral trainees and junior faculty have participated in BSCP programs. Several senior leaders of Health Advances will attend the event to celebrate BSCP’s accomplishments.

04.14.16

Sheldon Ng Joins Health Advances

We are delighted to announce that Sheldon Ng has joined Health Advances as a Vice President. Sheldon joins Health Advances’ San Francisco office, where he will bolster the biopharma leadership team through his experience in launch planning and commercial excellence.

“We are thrilled to add someone of Sheldon’s caliber to our growing San Francisco office. Sheldon’s expertise in launch excellence and commercial strategy will be a perfect complement to the existing work we do for biopharma. He also has significant experience in companion diagnostics and market access, two areas that we continue to see healthy client interest,” commented Vivek Mittal, Partner.

Sheldon comes to Health Advances with over a decade of strong consulting experience. He most recently headed Promidian Consulting’s Bay Area consulting practice where he focused on strategic engagements for some of the Bay Area’s leading biopharma companies. Previously, Sheldon was a successful Engagement Manager at IMS Consulting in San Francisco where he helped build a strong APAC practice.

Prior to his roles in consulting, Sheldon spent over a decade in industry, where he held business development roles at both Hana Biosciences and Guava Technologies. Early in his career, he was a scientist at Exelixis.

He earned his BA in Biological Sciences at Cornell and his MBA from the Kellogg School at Northwestern.

08.15: MedTech Strategist

Market Outlook: Simple Infusers: Unlocking the Potential of Insulin in Type 2 Diabetes

Marie Schiller, Arushi Agarwal, and Sheela Hegde

Simple insulin infusers are emerging as an important new tool to help people with type 2 diabetes gain better control of their disease. Although only one simple infuser product has been approved in the US to date, more are on the way and interest among physicians and payors is on the rise—all of which suggests a budding new market opportunity in the years ahead. Also Included: CeQur: Overcoming Barriers with PaQ Simple Insulin Infuser.

07.02.15

Juno Therapeutics and Celgene Ink 10 Year Deal

Read the latest blog post

The Celgene and Juno Therapeutics executive teams held a joint webcast on June 30th, 2015 to discuss their newly announced large-scale collaboration deal in T-cell technologies.

By Alison Munroe


“Health Advances delivered a comprehensive evaluation of our key assets and helped to drive the creation of a focused business development strategy to accelerate the achievement of our scientific and business objectives.”

Markus Warmuth
CEO
H3 Biomedicine